| Stereochemistry | ABSOLUTE |
| Molecular Formula | C43H50N8O5S |
| Molecular Weight | 790.973 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C1(CCNCC1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@@H](CC5=CSC6=C5C=CC=C6)NC(=O)C7CCNCC7
InChI
InChIKey=KUBPNVYPKPWGRJ-LIVOIKKVSA-N
InChI=1S/C43H50N8O5S/c44-42(56)43(16-20-46-21-17-43)51-41(55)34(22-27-8-2-1-3-9-27)49-39(53)35(23-29-25-47-33-12-6-4-10-31(29)33)50-40(54)36(48-38(52)28-14-18-45-19-15-28)24-30-26-57-37-13-7-5-11-32(30)37/h1-13,25-26,28,34-36,45-47H,14-24H2,(H2,44,56)(H,48,52)(H,49,53)(H,50,54)(H,51,55)/t34-,35+,36+/m0/s1
| Molecular Formula | C43H50N8O5S |
| Molecular Weight | 790.973 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Relamorelin (also known as BIM28131 or RM-131) is a synthetic, selective, prokinetic ghrelin analog that was developed for treatment of gastrointestinal motility disorders (such as chronic constipation and diabetic gastroparesis). Relamorelin was shown to relief symptoms such as nausea, fullness, bloating and abdominal pain. It is safe and well-tolerated in healthy individuals, and has no neurological or cardiovascular adverse effects, making this a promising drug with an advantage over other available therapies. A phase III clinical trial comparing the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) was still ongoing in 2019.
